ArticleGynecologic oncology2021

Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis.

Sarah A Ackroyd et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.